Trial Profile
An Open-Label, Exploratory Study of the Safety and Preliminary Efficacy of Danicamtiv in Stable Ambulatory Participants With Primary Dilated Cardiomyopathy Due to Either MYH7 or TTN Variants or Other Causalities
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2024
Price :
$35
*
At a glance
- Drugs Danicamtiv (Primary)
- Indications Dilated cardiomyopathy
- Focus Adverse reactions; Proof of concept
- Sponsors Bristol-Myers Squibb; MyoKardia
- 26 Mar 2024 Status changed from recruiting to discontinued.
- 20 Dec 2023 Planned End Date changed from 3 Jan 2025 to 19 Feb 2026.
- 20 Dec 2023 Planned primary completion date changed from 8 Dec 2023 to 29 Feb 2024.